ClinicalTrials.gg
CompletedNCT03182075EmRTUpdated Aug 13, 2026

Computerized Training for Individuals Diagnosed With Obsessive-Compulsive and Related Disorders

An interventional study of Computerized Training in Obsessive Compulsive Disorder, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This study aims to build on our understanding of aberrant emotional processing in OCD. The proposed project tests whether a computerized training aimed to alter emotional processes, can relieve repetitive thoughts and behaviors.

02

Conditions studied

  • Obsessive Compulsive Disorder

Keywords

  • Obsessive-Compulsive Disorder
  • OCD
  • Obsessive Personality Disorder
  • Compulsive Behavior
  • Personality Disorders
  • Mental Disorders
  • Anxiety Disorders
  • Impulsive Behavior
  • Cognition
  • Emotion
  • Emotional Regulation
03

In context

Obsessive-Compulsive Disorder

635 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.

This study's enrollment of 5 is below the median of 45 across 520 interventional studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 years old and older
  • primary diagnosis of OCD
  • sufficient severity of OCD symptoms
  • Stable on psychotropic or other medication
  • capacity to provide

Exclusion criteria

Exclusion criteria:

  • psychiatric or medical conditions that make participation unsafe
  • concurrent use of any medications that might increase the risk of participation
  • concurrent Cognitive-Behavioral therapy for OCD
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Active Training

    OCD and hoarding disorder participants will receive active emotional reactivity training (14 sessions) via computer.

    Behavioral: Computerized Training

  • Sham comparator
    Passive Training

    OCD and hoarding disorder participants will receive passive computerized training (14 sessions) via computer.

    Behavioral: Computerized Training

Interventions

  • BehavioralComputerized Training

    OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.

06

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive Compulsive Scale (for participants diagnosed with OCD)

    Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

    Time frame: up to 2 months

  2. Savings Inventory Revised Scale (for participants diagnosed with hoarding disorder)

    The SI-R is a 23-item questionnaire with 3 factor-analytically defined sub-scales for difficulty discarding, excessive clutter, and compulsive acquisition.

    Time frame: up to 2 months

07

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Nov 2018, 6 months.

Of 234 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's 6 months is below that.

Counting every sponsor, half of 237 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2017
First posted
Jun 9, 2017
StartActual
Apr 30, 2018
Primary completionActual
Nov 12, 2018
CompletionActual
Nov 12, 2018
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03182075
Responsible party
Carolyn Rodriguez (Assistant Professor, Stanford University) — Principal investigator
First posted
Jun 9, 2017
Start date
Apr 30, 2018
Primary completion
Nov 12, 2018
Completion
Nov 12, 2018
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion